Annual CFO
-$73.38 M
-$24.98 M-51.61%
31 December 2023
Summary:
Viking Therapeutics annual cash flow from operations is currently -$73.38 million, with the most recent change of -$24.98 million (-51.61%) on 31 December 2023. During the last 3 years, it has fallen by -$51.60 million (-236.94%). VKTX annual CFO is now -93731.20% below its all-time high of -$78.20 thousand, reached on 31 December 2013.VKTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$21.96 M
+$6.55 M+22.98%
30 September 2024
Summary:
Viking Therapeutics quarterly cash flow from operations is currently -$21.96 million, with the most recent change of +$6.55 million (+22.98%) on 30 September 2024. Over the past year, it has dropped by -$2.30 million (-11.72%).VKTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$74.25 M
-$2.30 M-3.20%
30 September 2024
Summary:
Viking Therapeutics TTM cash flow from operations is currently -$74.25 million, with the most recent change of -$2.30 million (-3.20%) on 30 September 2024. Over the past year, it has dropped by -$7.59 million (-11.38%).VKTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VKTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -51.6% | -11.7% | -11.4% |
| 3 y3 years | -236.9% | -101.0% | -82.3% |
| 5 y5 years | -291.2% | -546.3% | -373.3% |
VKTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -236.9% | at low | -258.0% | +23.0% | -82.3% | at low |
| 5 y | 5 years | -291.2% | at low | -546.3% | +23.0% | -373.3% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +23.0% | <-9999.0% | at low |
Viking Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$21.96 M(-23.0%) | -$74.25 M(+3.2%) |
| June 2024 | - | -$28.51 M(+364.8%) | -$71.94 M(+31.1%) |
| Mar 2024 | - | -$6.13 M(-65.2%) | -$54.87 M(-25.2%) |
| Dec 2023 | -$73.38 M(+51.6%) | -$17.64 M(-10.3%) | -$73.38 M(+10.1%) |
| Sept 2023 | - | -$19.66 M(+71.9%) | -$66.66 M(+10.2%) |
| June 2023 | - | -$11.44 M(-53.6%) | -$60.50 M(-3.2%) |
| Mar 2023 | - | -$24.64 M(+125.5%) | -$62.51 M(+29.2%) |
| Dec 2022 | -$48.40 M(+1.7%) | -$10.93 M(-19.1%) | -$48.40 M(-2.9%) |
| Sept 2022 | - | -$13.50 M(+0.4%) | -$49.82 M(+5.4%) |
| June 2022 | - | -$13.44 M(+27.7%) | -$47.25 M(+0.0%) |
| Mar 2022 | - | -$10.53 M(-14.7%) | -$47.24 M(-0.7%) |
| Dec 2021 | -$47.59 M(+118.5%) | -$12.35 M(+13.0%) | -$47.59 M(+16.9%) |
| Sept 2021 | - | -$10.93 M(-18.7%) | -$40.72 M(+16.0%) |
| June 2021 | - | -$13.43 M(+23.5%) | -$35.12 M(+23.9%) |
| Mar 2021 | - | -$10.88 M(+98.3%) | -$28.35 M(+30.2%) |
| Dec 2020 | -$21.78 M(-12.0%) | -$5.49 M(+3.1%) | -$21.78 M(-22.3%) |
| Sept 2020 | - | -$5.32 M(-20.1%) | -$28.03 M(+7.4%) |
| June 2020 | - | -$6.67 M(+55.0%) | -$26.11 M(+0.8%) |
| Mar 2020 | - | -$4.30 M(-63.4%) | -$25.90 M(+4.6%) |
| Dec 2019 | -$24.75 M(+32.0%) | -$11.74 M(+245.6%) | -$24.75 M(+57.8%) |
| Sept 2019 | - | -$3.40 M(-47.4%) | -$15.69 M(-11.8%) |
| June 2019 | - | -$6.46 M(+104.9%) | -$17.79 M(+7.2%) |
| Mar 2019 | - | -$3.15 M(+17.7%) | -$16.60 M(-11.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$18.75 M(+27.1%) | -$2.68 M(-51.3%) | -$18.75 M(-6.3%) |
| Sept 2018 | - | -$5.50 M(+4.4%) | -$20.02 M(+12.2%) |
| June 2018 | - | -$5.27 M(-0.6%) | -$17.85 M(+6.4%) |
| Mar 2018 | - | -$5.30 M(+34.4%) | -$16.78 M(+13.7%) |
| Dec 2017 | -$14.76 M(+33.3%) | -$3.95 M(+18.6%) | -$14.76 M(+11.2%) |
| Sept 2017 | - | -$3.33 M(-20.8%) | -$13.28 M(+5.4%) |
| June 2017 | - | -$4.20 M(+28.1%) | -$12.60 M(+8.4%) |
| Mar 2017 | - | -$3.28 M(+33.1%) | -$11.63 M(+5.0%) |
| Dec 2016 | -$11.07 M(+26.8%) | -$2.46 M(-7.1%) | -$11.07 M(-7.0%) |
| Sept 2016 | - | -$2.65 M(-17.7%) | -$11.91 M(-5.9%) |
| June 2016 | - | -$3.23 M(+18.4%) | -$12.65 M(+14.5%) |
| Mar 2016 | - | -$2.73 M(-17.4%) | -$11.05 M(+26.5%) |
| Dec 2015 | -$8.73 M(+448.7%) | -$3.30 M(-3.0%) | -$8.73 M(+48.7%) |
| Sept 2015 | - | -$3.40 M(+109.8%) | -$5.87 M(+90.5%) |
| June 2015 | - | -$1.62 M(+294.4%) | -$3.08 M(+62.1%) |
| Mar 2015 | - | -$410.90 K(-6.8%) | -$1.90 M(+19.5%) |
| Dec 2014 | -$1.59 M(+1935.0%) | -$441.00 K(-27.7%) | -$1.59 M(+38.3%) |
| Sept 2014 | - | -$609.80 K(+38.6%) | -$1.15 M(+112.8%) |
| June 2014 | - | -$439.90 K(+336.4%) | -$540.70 K(+388.4%) |
| Mar 2014 | - | -$100.80 K(+918.2%) | -$110.70 K(+1018.2%) |
| Dec 2013 | -$78.20 K | - | - |
| June 2013 | - | -$9900.00(<-9900.0%) | -$9900.00(<-9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
FAQ
- What is Viking Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Viking Therapeutics?
- What is Viking Therapeutics annual CFO year-on-year change?
- What is Viking Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Viking Therapeutics?
- What is Viking Therapeutics quarterly CFO year-on-year change?
- What is Viking Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Viking Therapeutics?
- What is Viking Therapeutics TTM CFO year-on-year change?
What is Viking Therapeutics annual cash flow from operations?
The current annual CFO of VKTX is -$73.38 M
What is the all time high annual CFO for Viking Therapeutics?
Viking Therapeutics all-time high annual cash flow from operations is -$78.20 K
What is Viking Therapeutics annual CFO year-on-year change?
Over the past year, VKTX annual cash flow from operations has changed by -$24.98 M (-51.61%)
What is Viking Therapeutics quarterly cash flow from operations?
The current quarterly CFO of VKTX is -$21.96 M
What is the all time high quarterly CFO for Viking Therapeutics?
Viking Therapeutics all-time high quarterly cash flow from operations is $0.00
What is Viking Therapeutics quarterly CFO year-on-year change?
Over the past year, VKTX quarterly cash flow from operations has changed by -$2.30 M (-11.72%)
What is Viking Therapeutics TTM cash flow from operations?
The current TTM CFO of VKTX is -$74.25 M
What is the all time high TTM CFO for Viking Therapeutics?
Viking Therapeutics all-time high TTM cash flow from operations is $0.00
What is Viking Therapeutics TTM CFO year-on-year change?
Over the past year, VKTX TTM cash flow from operations has changed by -$7.59 M (-11.38%)